Guardian Wealth Management Inc. Has $2.09 Million Stock Position in Johnson & Johnson (NYSE:JNJ)

Guardian Wealth Management Inc. raised its stake in Johnson & Johnson (NYSE:JNJ – Get Rating) by 3.8% in the 4th quarter, HoldingsChannel.com reports. The firm owned 11,848 shares of the company’s stock after buying an additional 438 shares during the quarter. Johnson & Johnson comprises 2.1% of Guardian Wealth Management Inc.’s investment portfolio, making the stock its 15th largest position. Guardian Wealth Management Inc.’s holdings in Johnson & Johnson were worth $2,093,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Glassy Mountain Advisors Inc. purchased a new stake in shares of Johnson & Johnson in the fourth quarter worth approximately $35,000. Retirement Financial Solutions LLC purchased a new stake in shares of Johnson & Johnson in the fourth quarter worth approximately $40,000. TD Capital Management LLC purchased a new stake in shares of Johnson & Johnson in the third quarter worth approximately $48,000. VitalStone Financial LLC purchased a new stake in shares of Johnson & Johnson during the fourth quarter valued at approximately $52,000. Finally, Iron Horse Wealth Management LLC increased its position in shares of Johnson & Johnson by 112.8% during the fourth quarter. Iron Horse Wealth Management LLC now owns 300 shares of the company’s stock valued at $53,000 after acquiring an additional 159 shares during the last quarter. 67.94% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Price Performance

Johnson & Johnson stock opened at $154.41 on Friday. Johnson & Johnson has a one year low of $150.11 and a one year high of $183.35. The business has a fifty day moving average price of $159.89 and a 200-day moving average price of $165.86. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.07 and a quick ratio of 0.85. The firm has a market capitalization of $401.27 billion, a P/E ratio of 32.30, a PEG ratio of 2.67 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ – Get Rating) last posted its earnings results on Tuesday, April 18th. The company reported $2.68 EPS for the quarter, topping the consensus estimate of $2.51 by $0.17. Johnson & Johnson had a return on equity of 36.13% and a net margin of 13.22%. The business had revenue of $24.75 billion during the quarter, compared to analysts’ expectations of $23.61 billion. During the same period in the previous year, the business earned $2.67 earnings per share. The firm’s revenue was up 5.6% on a year-over-year basis. As a group, equities research analysts forecast that Johnson & Johnson will post 10.66 EPS for the current year.

Johnson & Johnson Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 6th. Investors of record on Tuesday, May 23rd will be given a dividend of $1.19 per share. This represents a $4.76 annualized dividend and a yield of 3.08%. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.13. The ex-dividend date of this dividend is Monday, May 22nd. Johnson & Johnson’s payout ratio is presently 99.58%.

Insider Buying and Selling

In related news, insider James D. Swanson sold 1,062 shares of the business’s stock in a transaction dated Monday, March 6th. The stock was sold at an average price of $154.66, for a total transaction of $164,248.92. Following the completion of the transaction, the insider now directly owns 9,215 shares in the company, valued at $1,425,191.90. The transaction was disclosed in a document filed with the SEC, which is available through this link. 0.20% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of analysts recently commented on the company. Raymond James decreased their price target on Johnson & Johnson from $185.00 to $181.00 and set an “outperform” rating for the company in a research report on Wednesday, April 19th. Guggenheim assumed coverage on Johnson & Johnson in a research report on Tuesday, February 28th. They set a “neutral” rating and a $161.00 price target for the company. Morgan Stanley increased their price target on Johnson & Johnson from $179.00 to $183.00 and gave the company an “equal weight” rating in a research report on Wednesday, April 19th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a research report on Wednesday, February 1st. Finally, StockNews.com began coverage on Johnson & Johnson in a report on Thursday, May 18th. They set a “strong-buy” rating for the company. Seven investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $173.00.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.